Olajide Masha, MD
Psychiatry · Rosenberg, TXNPI 1457553505
Payments from drug & device makers
Across 790 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Sunovion Pharmaceuticals Inc.$1K
- plus $6K from 21 others
What the payments were for
- Food & beverage$15,19896%
- Education$6544%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 97 | $2,168 |
| Otsuka America Pharmaceutical, Inc. | 99 | $2,107 |
| Alkermes, Inc. | 83 | $1,996 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 65 | $1,520 |
| Teva Pharmaceuticals USA, Inc. | 57 | $1,388 |
| Sunovion Pharmaceuticals Inc. | 71 | $1,080 |
| Indivior Inc. | 44 | $745 |
| Corium, LLC | 55 | $723 |
| Neurocrine Biosciences, Inc. | 36 | $710 |
| Ironshore Pharmaceuticals Inc. | 38 | $603 |
| Supernus Pharmaceuticals, Inc. | 26 | $542 |
| E.r. Squibb & Sons, L.L.C. | 19 | $479 |
| AbbVie(2 entities) | 29 | $474 |
| Tris Pharma Inc | 15 | $228 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $199 |
| Axsome Therapeutics, Inc. | 6 | $183 |
| Vanda Pharmaceuticals Inc. | 9 | $181 |
| Rhodes Pharmaceuticals L.p. | 6 | $141 |
| Shire North American Group Inc | 9 | $123 |
| Noven Therapeutics, LLC | 4 | $76 |
| Luye Pharma (USA) Ltd. | 2 | $48 |
| Neos Therapeutics, LP | 2 | $34 |
| Adlon Therapeutics L.p. | 2 | $29 |
| Lundbeck LLC | 1 | $26 |
| Livanova USA, Inc. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,993
- CAPLYTA$613
- ARISTADA INITIO$498
- ABILIFY MAINTENA$243
- ABILIFY ASIMTUFII$243
- INVEGA SUSTENNA$242
- REXULTI$242
- INVEGA$150
- INVEGA TRINZA$132
- Azstarys$124
- COBENFY$122
- LATUDA$121
- QELBREE$119
- UZEDY$109
- Auvelity$104
- Austedo XR$102
How this compares
$15,851 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 223 | $745,216 |
| AustedoDeutetrabenazine | 24 | $144,155 |
| PerserisRisperidone | 31 | $68,589 |
| NuedextaDextromethorphan Hbr/Quinidine | 50 | $63,948 |
| RexultiBrexpiprazole | 39 | $57,664 |
| FanaptIloperidone | 21 | $44,962 |
| Abilify MaintenaAripiprazole | 14 | $38,204 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $37,110 |
| Lurasidone Hcl | 143 | $34,712 |
| Divalproex Sodium ErDivalproex Sodium | 393 | $12,066 |
| Paliperidone ErPaliperidone | 67 | $10,868 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $9,815 |
| TrintellixVortioxetine Hydrobromide | 14 | $7,127 |
| Olanzapine | 201 | $6,003 |
| Chlorpromazine Hcl | 46 | $4,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $2,168 | $745,216223 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,388 | $144,15524 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $2,107 | $95,86853 claims |
| Indivior Inc.Perseris | $745 | $68,58931 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $181 | $44,96221 claims |
| Alkermes, Inc.Lybalvi | $1,996 | $37,11017 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $199 | $16,94237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Rosenberg
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.